Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Rhea-AI Summary

Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on March 15, 2022, at 8:30 a.m. ET to discuss its financial results for 2021 and recent business highlights. The call will provide insights into the company's progress in developing therapeutics for rare hemoglobin disorders and other serious diseases. Notably, Imara is advancing tovinontrine (IMR-687) in Phase 2b trials for sickle cell disease and beta-thalassemia, and plans to initiate a Phase 2 trial of the drug in heart failure by Q2 2022.

Positive

• Imara is advancing tovinontrine (IMR-687) in Phase 2b trials for sickle cell disease and beta-thalassemia.
• Expected Phase 2 clinical trial initiation for tovinontrine in heart failure with preserved ejection fraction (HFpEF) in Q2 2022.

Negative

• None.

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.

A live webcast will be available under “Events and Presentations” in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800-3873 (international) and referring to conference ID 5889355. A replay of the webcast will be archived on the Imara website following the presentation.

About Imara
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Imara is advancing tovinontrine (IMR-687), a highly selective, potent small molecule inhibitor of PDE9 that is an oral, potentially disease-modifying treatment in Phase 2b clinical trials for sickle cell disease and beta-thalassemia. Imara expects to initiate a Phase 2 clinical trial of tovinontrine in heart failure with preserved ejection fraction (HFpEF) in the second quarter of 2022. Imara is also advancing IMR-261, an oral activator of nuclear factor erythroid 2–related factor 2, or Nrf2. For more information, please visit www.imaratx.com.

Media Contact:
Marin Bergman
Ten Bridge Communications
818-516-2746
marin@tenbridgecommunications.com

Investor Contact:
Michael Gray
617-835-4061
mgray@imaratx.com

FAQ

What is the date of the upcoming conference call for Imara Inc.?

Imara Inc. will host a conference call on March 15, 2022.

What financial results will Imara announce on March 15, 2022?

Imara will discuss its financial results for the year ended December 31, 2021.

What is the ticker symbol for Imara Inc.?

The ticker symbol for Imara Inc. is IMRA.

What clinical trials is Imara currently conducting?

Imara is conducting Phase 2b trials for tovinontrine in sickle cell disease and beta-thalassemia.

When does Imara plan to initiate a Phase 2 trial for heart failure?

Imara plans to initiate a Phase 2 trial for heart failure in the second quarter of 2022.